ClinicalTrials.gg
RecruitingNCT06786234Updated Jun 16, 2026

A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

A Phase 2 interventional study of STP938 in Essential Thrombocythaemia, sponsored by Step Pharma, SAS. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Step Pharma, SAS · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Thrombocythemia, Essential with a site in France — 7 open to participants now, 12 under way, 5 of them phase 3. Thrombocythemia, Essential · France.

Planned enrollment
23rd of 27
50 · median 160
Started
2025
the only one that year
Phase 2
5 of 37
1 open now
Primary completion
2028-06
later than 9 of 11 live
Registered
35th of 37
by date

Among the 37 studies in Thrombocythemia, Essential with a site in France, this one is the 23rd largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, reaches primary completion later than 9 of the 11 other live ones, and was the 35th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

7 of the 37 studies in Thrombocythemia, Essential with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Thrombocythemia, Essential with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are:

  • Does STP938 control platelet counts
  • Does STP938 control platelet counts without inducing unwanted side effects

Participants will:

  • Take STP938 every day for up to 12 months.
  • Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests.
  • Complete a questionnaire about symptoms once a month.
Read the detailed description

The aim of the study is to assess a new drug called STP938 for the treatment of essential thrombocythaemia (ET). The study with assess how effective STP938 in treating ET, and also assess any side effects of taking the drug. The study will enrol individuals with high risk ET who require treatment to lower their platelet count. Individuals enrolling on the study will have already tried treatment with hydroxycarbamide (also known as hydroxyurea) but are in need of a different treatment as hydroxycarbamide either did not control the platelet count or produced unwanted side effects.

STP938 is a new class of drug that inhibits the enzyme cytidine triphosphate synthase 1 (CTPS1). Inhibition of CTPS1 is a novel way of lowering the platelet count. This study is a phase 1b, open-label, multicentre trial. Participants will receive STP938 capsules every day, in cycles of 28 days, for approximately 12 months. Participants may continue to receive study drug for a longer period, so long as it is controlling the platelet count and not causing side effects. During the study, participants will visit the study site about 26 times (2 times per cycle) over an estimated 12 months. Once the treatment is complete, safety follow-up visit(s) will occur to make sure the participant is not experiencing any adverse effects. The following study procedures will be performed: (a) physical examinations (b) ECGs (c) blood tests, (d) urine tests (e) CT/MRI scans (f) bone marrow biopsies (g) drug administration (h) study drug blood level tests and (i) gene testing.

03

Conditions studied

  • Essential Thrombocythaemia

Keywords

  • Essential Thrombocythemia
  • High risk
  • Resistant to or Intolerant of Hydroxycarbamide Therapy
  • Resistant to or Intolerant of Hydroxyurea Therapy
  • Oral therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults aged 18 years or older
  • A confirmed diagnosis of ET according to World Health Organisation (WHO) or British Society for Haematology (BSH) criteria.
  • Meeting criteria for high risk ET.
  • Raised count (>600 x109/L) requiring cytoreductive therapy.
  • >1.0 x109/L.
  • Either intolerant of or resistant to hydroxycarbamide having met any one of the criteria at any point in their disease whilst receiving hydroxycarbamide.
  • Adequate hepatic function.
  • Adequate blood coagulation parameters.
  • (ECOG) status of 0-2.

Key Exclusion Criteria:

  • Subjects currently or recently receiving cytoreductive therapy for the treatment of essential thrombocythaemia (wash out periods apply).
  • Subjects who have received any agents for the treatment of essential thrombocythaemia within 4 weeks before enrolment or less than 5 half-lives since completion of prior therapy, whichever is shorter.
  • Proven or suspected transformation to polycythaemia vera, myelofibrosis, myelodysplasia, acute myeloid leukaemia or another myeloid neoplasm.
  • Known malabsorption syndrome or other condition that may impair absorption of study medication (e.g. gastrectomy).
  • Previous splenectomy.
  • Any uncontrolled intercurrent illness.
  • subjects with increased risk of opportunistic infections.
  • Known active or chronic or active virus (HCV) infection.
  • Pregnant females, breastfeeding females, and women of child bearing age or males not willing to comply with requirements.
  • Known to any of the used in the formulation of the study drug.
  • interval >470 msec based on averaged triplicate (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Phase 2

    Adjustable dose levels with STP938 administered as oral therapy

    Drug: STP938

Interventions

  • DrugSTP938

    At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.

06

What researchers measure

Primary outcomes

  1. Clinical Efficacy

    Complete and partial response rates per European LeukemiaNet criteria

    Time frame: Through study completion, an average of 12 months

  2. Safety and Tolerability

    Toxicity profile based on National Cancer Institute Common Terminology Criteria for Adverse Events

    Time frame: Through study completion, an average of 12 months

Secondary outcomes

  1. Durability of Response to STP938

    Time from achieving response to loss of response

    Time frame: Through study completion, an average of 12 months

  2. Impact of STP938 on Disease-Related Complications

    Prevalence of haemorrhagic complications, thromboembolic events and disease transformation.

    Time frame: Through study completion, an average of 12 months

Other outcomes

  1. Patient Reported Outcomes and Symptom Burden

    Myeloproliferative Neoplasm Symptom Assessment Form (18 item). Minimum value is zero (0); the maximum value is 180. A score of zero equates to absence of symptoms, higher scores equate to worse outcome.

    Time frame: Through study completion, an average of 12 months

  2. Molecular Response

    Change in Variant Allele Fraction: For known ET-associated mutations.

    Time frame: Through study completion, an average of 12 months

  3. Bone Marrow Histology

    Changes in Histological Appearances

    Time frame: Screening and Cycle 12 (each cycle is 28 days)

  4. Spleen Volume

    Change in Spleen Volume: Measured by MRI or CT scan.

    Time frame: Through study completion, an average of 12 months

07

Study locations

13 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 22, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786234
Lead sponsor
Step Pharma, SAS
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jun 18, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Carol M MacLean, PhD
Contact
STP938-301@step-ph.com
+33 1 86 26 43 56
Maureen Higgins, PhD, MBA
Contact
STP938-301@step-ph.com
+33 1 86 26 43 56
Maureen Higgins
study director · Step Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dencatistat

Start the discussion